Plasma uric acid and spironolactone response in healthy subjects.
作者信息
Ramsay L E, Shelton J R, Harrison I R
出版信息
Br J Clin Pharmacol. 1977 Apr;4(2):247-9. doi: 10.1111/j.1365-2125.1977.tb00706.x.
Abstract
摘要
相似文献
1
Plasma uric acid and spironolactone response in healthy subjects.健康受试者的血浆尿酸与螺内酯反应
Br J Clin Pharmacol. 1977 Apr;4(2):247-9. doi: 10.1111/j.1365-2125.1977.tb00706.x.
2
Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.验证血浆和尿中坎利酮用于测定螺内酯生物利用度——片剂与溶液/混悬液的比较
Int J Clin Pharmacol Biopharm. 1977 May;15(5):205-10.
3
Canrenone--the principal active metabolite of spironolactone?坎利酮——螺内酯的主要活性代谢物？
Br J Clin Pharmacol. 1976 Aug;3(4):607-12. doi: 10.1111/j.1365-2125.1976.tb04883.x.
4
Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.微粉化对螺内酯生物利用度和药理活性的影响。
J Clin Pharmacol. 1982 Aug-Sep;22(8-9):410-7. doi: 10.1002/j.1552-4604.1982.tb02694.x.
5
Spironolactone and canrenoate-K: relative potency at steady state.螺内酯和坎利酸钾：稳态时的相对效价。
Clin Pharmacol Ther. 1977 May;21(5):602-9. doi: 10.1002/cpt1977215602.
6
Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.正常人体中醛固酮拮抗剂的生物测定：治疗前血浆尿酸水平与明显药物反应之间的关系。
Br J Clin Pharmacol. 1975 Jun;2(3):271-6. doi: 10.1111/j.1365-2125.1975.tb01587.x.
7
Spironolactone. II. Bioavailability.螺内酯。二、生物利用度。
Clin Pharmacol Ther. 1976 Feb;19(2):170-6. doi: 10.1002/cpt1976192170.
8
[Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].苄氟噻嗪与螺内酯联合应用的药代动力学研究及生物利用度
Arzneimittelforschung. 1986 Mar;36(3):490-5.
9
Factors influencing comparative bioavailability of spironolactone tablets.影响螺内酯片相对生物利用度的因素。
J Pharm Sci. 1977 Oct;66(10):1429-32. doi: 10.1002/jps.2600661020.
10
A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.三种螺内酯片剂制剂的溶出度和生物利用度特征比较，包括两种螺内酯代谢物的初步数据。
J Int Med Res. 1976;4(2):86-95. doi: 10.1177/030006057600400202.
引用本文的文献
1
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.合并症对痛风和高尿酸血症的影响：患病率及治疗选择的最新进展
BMC Med. 2017 Jul 3;15(1):123. doi: 10.1186/s12916-017-0890-9.
2
The influence of sodium and potassium supplements on the diuretic responses to frusemide administration in normal subjects.钠和钾补充剂对正常受试者使用速尿后利尿反应的影响。
Br J Pharmacol. 1978 Oct;64(2):285-92. doi: 10.1111/j.1476-5381.1978.tb17302.x.
本文引用的文献
1
A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.一种用于测定人血浆中主要螺内酯（安体舒通）代谢物的荧光测定法。
J Pharmacol Exp Ther. 1962 Mar;135:312-6.
2
Determination of uric acid. An adaptation of the Archibald method on the autoanalyzer.尿酸的测定。自动分析仪上阿奇博尔德方法的一种改进。
Clin Chem. 1967 Jan;13(1):12-8.
3
Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.正常人体中醛固酮拮抗剂的生物测定：治疗前血浆尿酸水平与明显药物反应之间的关系。
Br J Clin Pharmacol. 1975 Jun;2(3):271-6. doi: 10.1111/j.1365-2125.1975.tb01587.x.
4
A relationship between plasma uric acid concentration and the apparent response to frusemide in normal subjects.正常受试者血浆尿酸浓度与呋塞米明显反应之间的关系。
Br J Clin Pharmacol. 1975 Aug;2(4):361-2. doi: 10.1111/j.1365-2125.1975.tb02786.x.
5
Relative potency of prorenoate and spironolactone in normal man.在正常男性体内普乐烯酸酯与螺内酯的相对效价
Clin Pharmacol Ther. 1975 Oct;18(4):391-400. doi: 10.1002/cpt1975184391.
Zotero 插件